

AstraZeneca – Call For Grant Applications
CGA Rheumatology SLE General 2021-02

Submission Deadline	Rolling review/support decisions, with submission deadline of October 6 th at 9 am EST
Primary Area of Focus	Rheumatology
Therapeutic Area	Systemic Lupus Erythematosus (SLE)
Burden to the Patient	<p>Patients with SLE who have been properly diagnosed have many challenges, including:</p> <ul style="list-style-type: none"> • Daily symptom management to maximize quality-of-life • Distress over timing and severity of next flare • Toxicities associated with conventional immunosuppressants, including glucocorticoids • Advocating for individualized treatments for better symptom management and quality-of-life
Healthcare Burden	<p>SLE is a chronic, multisystem autoimmune disorder that impacts approximately 204,000 Americans, primarily women of child-bearing age.</p> <p>Rheumatologists face substantial challenges in the diagnosis and management of patients with SLE, owing to the:</p> <ul style="list-style-type: none"> • Diverse symptomatology due to the involvement of different organ systems • Diverse patient populations, with its prevalence being 2-3 times greater among women of color • Complexity of the pathophysiology of SLE and targets being explored in clinical trials • Limited awareness of current clinical trials and results <ul style="list-style-type: none"> • Limited experience with biologic therapy in the management of patients with moderate-to-severe SLE • Underappreciation of the impact of conventional therapies on the accumulation of organ damage and SLE-related comorbidities
Educational Program	<p>Format that:</p> <ul style="list-style-type: none"> • Takes into account: <ul style="list-style-type: none"> ○ Content tailored to the specific needs of and learning styles of the proposed audience ○ Time constraints of the learner • Faculty from diverse backgrounds who represent the diversity of patients with SLE • Leverages the latest digital technologies for learner engagement • Employs educational strategies for maximal retention and application of content by tailoring to the specific needs of and learning styles of the proposed audience • Has proven success in translating knowledge into practice change (eg, grand rounds; small group discussions; workshops; quality improvement; etc)
Budget	≤ \$250,000
Successful submission	<ul style="list-style-type: none"> • Independently-developed application, providing rationale/basis for and detailed description of the goals, learning objectives, educational strategy, format, and execution and measurement/analysis of program outcomes • Specific root cause(s) of identified barriers to care upon which the program is being designed • Outcomes from previously executed program
CGA Code	CGA_Rheumatology_SLE_General_2021-02
Website URL	https://www.astrazenecagrants.com/us-grants.html

Program Requirements:

The Program must be planned and executed as if an accredited activity and fully compliant with the criteria and/or standards of commercial support for ACCME, AAFP, AOA, ACPE, ANCC, AANP, or NCCPA. Furthermore, the program will be educational and non-promotional in nature and will be planned, designed and implemented in accordance with the U.S. Food and Drug Administration's Guidance on Industry-Supported Scientific and Educational Activities ("Policy Statement").

The Policy Statement and the ACCME Standards require, among other things, that (i) Institution conduct the Program independently and without control or influence by AstraZeneca over the Program's planning, content (including the selection of speakers or moderators), or execution; (ii) the Program be free of commercial bias for or against any product; (iii) Institution make meaningful disclosure of AstraZeneca support of the Program and any prior relationship between Institution and AstraZeneca, and the relationship, if any, between AstraZeneca and the speakers selected by Institution; and (iv) AstraZeneca not engage in, and Institution not permit any other sponsor to engage in, promotional activities in or near the Program room or advertise its products in any materials disseminated as part of the Program.

In addition, Institution is required by the Policy Statement and, if applicable, accreditation standards to ensure that any product discussions at the Program be accurate, objective, balanced and scientifically rigorous. This includes a balanced discussion of each product and of treatment alternatives, that limitations on data be disclosed, that unapproved uses be identified as such, and that for live presentations there be opportunities for questioning or debate.